Speedy EU Assessment On Cards For AZ’s Durvalumab

 
• By Maureen Kenny
  
Business Accelerator Program
Durvalumab could benefit from accelerated assessment in the EU • Source: Shutterstock

More from Immuno-oncology

More from Anticancer